Predictors of accelerated FEV 1 decline in adults with airflow limitation-Findings from the Health2006 cohort.

Publisher: SAGE Publications Country of Publication: England NLM ID: 101197408 Publication Model: Print Cited Medium: Internet ISSN: 1479-9731 (Electronic) Linking ISSN: 14799723 NLM ISO Abbreviation: Chron Respir Dis Subsets: MEDLINE

Publication: London : SAGE Publications
Original Publication: London : Arnold, c2004-

Asthma/*physiopathology ; Dyspnea/*physiopathology ; Forced Expiratory Volume/*physiology ; Smoking/*physiopathology; Age Factors ; Aged ; Asthma/epidemiology ; Breath Tests ; Denmark/epidemiology ; Dermatitis, Atopic/epidemiology ; Disease Progression ; Dyspnea/epidemiology ; Female ; Follow-Up Studies ; Humans ; Hypersensitivity, Immediate/epidemiology ; Lung Diseases, Obstructive/epidemiology ; Lung Diseases, Obstructive/physiopathology ; Male ; Middle Aged ; Nitric Oxide/metabolism ; Obesity/epidemiology ; Physical Fitness/physiology ; Sex Factors ; Skin Tests ; Smoking/epidemiology ; Spirometry ; Vital Capacity/physiology ; Waist-Hip Ratio

To investigate predictors of accelerated decline in forced expiratory volume in 1 s (FEV 1 ) in individuals with preexisting airflow limitation (AL). Participants in the Health2006 baseline study aged ≥ 35 with FEV 1 / forced vital capacity (FVC) < lower limit of normal (LLN) were invited for a 10-year follow-up. At both examinations, data were obtained on demographics, spirometry, fitness level, allergy, and exhaled nitric oxide. We used multiple regression modeling to predict the annual decline in FEV 1 , reported as regression coefficients ( R) and 95% confidence intervals (CIs). A total of 123 (43% of those invited) participated in the follow-up examination, where more had exercise-induced dyspnea but fewer had asthma symptoms. Being female ( R = -29.8 ml, CI: -39.7 to -19.8), diagnosed with asthma ( R = -13.7, CI: -20.4 to -7.0) or atopic dermatitis ( R = -29.0, CI: -39.7 to -18.4), and having current asthma symptoms or nightly respiratory symptoms ( R = -22.1, CI: -31.9 to -12.4 and R = -14.3, CI: -19.9 to -8.7, respectively) were significantly associated with a steeper decline in FEV 1 . Although to a smaller extent, a steeper decline was also predicted by age, baseline FEV 1 , waist/hip-ratio, and number of pack-years smoked. In individuals with preexisting AL, being female and having ever or current respiratory symptoms were associated with an accelerated annual decline in FEV 1 .

PLoS One. 2018 May 16;13(5):e0197250. (PMID: 29768509)
N Engl J Med. 2015 Sep 24;373(13):1241-9. (PMID: 26398072)
Respir Med. 2011 Jun;105(6):907-15. (PMID: 21295958)
N Engl J Med. 2007 Feb 22;356(8):775-89. (PMID: 17314337)
Am J Respir Crit Care Med. 2010 Sep 1;182(5):598-604. (PMID: 20522794)
Eur Respir J. 2008 Oct;32(4):844-53. (PMID: 18827152)
Br Med J. 1977 Jun 25;1(6077):1645-8. (PMID: 871704)
Am J Respir Crit Care Med. 2002 Sep 1;166(5):675-9. (PMID: 12204864)
Eur Respir J. 2008 Aug;32(2):344-9. (PMID: 18508818)
Thorax. 2015 Jul;70(7):683-91. (PMID: 25948695)
N Engl J Med. 1991 Aug 8;325(6):388-92. (PMID: 2062329)
Thorax. 2006 Feb;61(2):105-10. (PMID: 16308336)
N Engl J Med. 2011 Sep 29;365(13):1184-92. (PMID: 21991892)
BMC Pulm Med. 2012 Mar 21;12:10. (PMID: 22436173)
N Engl J Med. 2008 Oct 9;359(15):1543-54. (PMID: 18836213)
Am J Respir Crit Care Med. 1995 Aug;152(2):609-12. (PMID: 7543345)
Int J Chron Obstruct Pulmon Dis. 2017 Mar 17;12:907-922. (PMID: 28360514)
Discov Med. 2013 Apr;15(83):243-9. (PMID: 23636141)
Eur Respir J. 2018 Mar 29;51(3):. (PMID: 29449425)
Am J Respir Crit Care Med. 2005 Apr 15;171(8):912-30. (PMID: 15817806)
Eur J Prev Cardiol. 2013 Dec;20(6):1088-94. (PMID: 23022702)
Lancet Respir Med. 2018 Jul;6(7):535-544. (PMID: 29628376)
Am Rev Respir Dis. 1988 May;137(5):1119-23. (PMID: 3195811)
Eur Respir J. 2014 Jan;43(1):54-63. (PMID: 23563262)
Respir Med. 2007 Mar;101(3):525-30. (PMID: 16908127)
Int J Clin Pract. 2015 Mar;69(3):336-49. (PMID: 25363328)
Eur Respir J. 2005 Aug;26(2):319-38. (PMID: 16055882)
Am J Respir Crit Care Med. 2005 Jan 15;171(2):109-14. (PMID: 15486340)
Sleep Breath. 2002 Dec;6(4):161-73. (PMID: 12524569)
Int J Chron Obstruct Pulmon Dis. 2018 Jun 21;13:1979-1986. (PMID: 29950827)
Ann Am Thorac Soc. 2018 Feb;15(2):200-208. (PMID: 28957643)
Int J Epidemiol. 2014 Apr;43(2):568-75. (PMID: 23615486)
JAMA. 2016 Apr 5;315(13):1378-93. (PMID: 27046366)
N Engl J Med. 1998 Oct 22;339(17):1194-200. (PMID: 9780339)
Lancet Respir Med. 2017 May;5(5):426-434. (PMID: 28389225)
Eur Heart J. 2007 Jun;28(11):1374-81. (PMID: 17242007)
Am J Respir Crit Care Med. 1999 Dec;160(6):1856-61. (PMID: 10588597)
N Engl J Med. 2015 Jul 9;373(2):111-22. (PMID: 26154786)
ERJ Open Res. 2018 Feb 16;4(1):. (PMID: 29707563)
Am J Respir Crit Care Med. 1999 Jan;159(1):179-87. (PMID: 9872837)
Eur Respir J. 2009 Sep;34(3):588-97. (PMID: 19460786)
Eur Respir J Suppl. 1993 Mar;16:5-40. (PMID: 8499054)
J Appl Physiol (1985). 2010 Jan;108(1):206-11. (PMID: 19875713)
Thorax. 2006 Feb;61(2):100-4. (PMID: 16443705)
Chest. 2010 Jun;137(6):1345-53. (PMID: 20363841)
N Engl J Med. 1994 Sep 15;331(11):700-5. (PMID: 8058076)
CMAJ. 2016 Oct 4;188(14):1004-1011. (PMID: 27486205)

Keywords: Airflow limitation; asthma; chronic obstructive pulmonary disease; lung function decline; respiratory symptoms

31C4KY9ESH (Nitric Oxide)

Date Created: 20190605 Date Completed: 20200804 Latest Revision: 20200804

20240829

PMC6547172

10.1177/1479973119838278

31159575